Laboratorios Buxton
Date: Aug 2019
Client: Laboratorios Buxton
Counterparty: Eurofarma
Industry: Healthcare
Amount: Undisclosed amount
Transaction:
Financial advisor to the shareholders of Laboratorios Buxton on the sale of the company to Brazil's Eurofarma.
Buxton is an Argentine pharmaceutical laboratory founded in 2003 by Roberto Busnelli (former shareholder of Rontag), engaged in the production, marketing and sale of own prescription medicines to specific segments of the Argentine pharmaceutical market. Buxton main therapeutic areas include (i) central nervous system (neurology/psychiatry), (ii) fertility, (iii) urology, and (iv) rheumatology. Buxton’s product portfolio includes own products – approx. 50% of revenues, mainly in neurology and rheumatology – and products licensed from international companies specialized in certain therapeutic areas – approx. 50% of revenues, mainly in fertility and urology-.
Eurofarma is one of the largest pharmaceutical companies in Brazil. With operations in more than 20 countries in South and Central America, the Caribbean and Africa, and 9 manufacturing plants strategically located in Latin America, Eurofarma is positioned in the major pharmaceutical segments: Medical Prescription and OTC, Generics, Hospital, Bidding, Oncology, Third Party Services and Veterinary. The company has a broad portfolio that meets all medical specialties, and which is a reference in the central nervous system, anti-infective and hormonal drugs.
Aug 2019
Financial advisor to
on the sale of 100% of the shares to
Undisclosed amount
Similar transactions
Nov 2021
Financial advisor to
on the sale of 34% of the shares to
With this transaction, Virbac completes the acquisition of 100% of the company since the initial purchase in 2012
Leer más
